Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP) manufacturing campus to Biogen Inc. This arrangement expands upon the capacity sharing manufacturing alliance Eisai and Biogen have had in place at the RTP facility since early 2013. Under this new agreement, Biogen will continue to manufacture oral solid-dose products for Eisai. In addition, Eisai has entered into a new manufactu...